NASDAQ:NEPT - Neptune Technologies & Bioressources Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $3.06 -0.01 (-0.33 %) (As of 07/18/2018 02:37 PM ET)Previous Close$3.10Today's Range$3.03 - $3.1352-Week Range$0.70 - $4.46Volume23,202 shsAverage Volume2.15 million shsMarket Capitalization$243.98 millionP/E RatioN/ADividend YieldN/ABeta1.36 Company ProfileFinancialsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neptune Technologies & Bioressources Inc., a nutrition products company, produces and commercializes nutraceutical products and turnkey solutions primarily for omega-3 softgel capsules and liquids. It offers specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils, as well as pet supplements. The company's custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Technologies & Bioressources Inc. has an agreement with Tetra Bio-Pharma Inc. for the co-development, commercialization, and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets. The company was founded in 1925 and is headquartered in Laval, Canada. Receive NEPT News and Ratings via Email Sign-up to receive the latest news and ratings for NEPT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:NEPT CUSIPN/A Webneptunecorp.com Phone45-0687-2262 Debt Debt-to-Equity RatioN/A Current Ratio3.30 Quick Ratio2.84 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.56 million Price / Sales11.24 Cash Flow$0.2066 per share Price / Cash14.81 Book Value$0.86 per share Price / Book3.56 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares79,210,000Market Cap$243.98 Neptune Technologies & Bioressources (NASDAQ:NEPT) Frequently Asked Questions What is Neptune Technologies & Bioressources' stock symbol? Neptune Technologies & Bioressources trades on the NASDAQ under the ticker symbol "NEPT." How were Neptune Technologies & Bioressources' earnings last quarter? Neptune Technologies & Bioressources Inc (NASDAQ:NEPT) issued its quarterly earnings data on Wednesday, October, 12th. The biotechnology company reported ($0.02) EPS for the quarter. The biotechnology company had revenue of $8.91 million for the quarter. View Neptune Technologies & Bioressources' Earnings History. What is the consensus analysts' recommendation for Neptune Technologies & Bioressources? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neptune Technologies & Bioressources in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Neptune Technologies & Bioressources' key competitors? Some companies that are related to Neptune Technologies & Bioressources include TG Therapeutics Inc common stock (TGTX), Omeros (OMER), Epizyme (EPZM), Karyopharm Therapeutics (KPTI), Dynavax Technologies (DVAX), MacroGenics (MGNX), Rhythm Pharmaceuticals (RYTM), CytomX Therapeutics (CTMX), Assembly Biosciences (ASMB), ANI Pharmaceuticals Inc Common Stock (ANIP), Amarin (AMRN), Homology Medicines (FIXX), NuCana (NCNA), Eidos Therapeutics (EIDX) and Inflarx (IFRX). Who are Neptune Technologies & Bioressources' key executives? Neptune Technologies & Bioressources' management team includes the folowing people: Mr. James S. Hamilton, Pres, CEO & DirectorMr. Mario Paradis, VP & CFOMr. Marc Vaugeois, VP of SalesMr. Michel Timperio, Pres of Cannabis Bus.Mr. François-Karl Brouillette, VP of Science & Innovation of Nutraceutical Bus. Has Neptune Technologies & Bioressources been receiving favorable news coverage? Headlines about NEPT stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neptune Technologies & Bioressources earned a coverage optimism score of 0.15 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.50 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Who are Neptune Technologies & Bioressources' major shareholders? Neptune Technologies & Bioressources' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.05%). View Institutional Ownership Trends for Neptune Technologies & Bioressources. Which institutional investors are buying Neptune Technologies & Bioressources stock? NEPT stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Neptune Technologies & Bioressources. How do I buy shares of Neptune Technologies & Bioressources? Shares of NEPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neptune Technologies & Bioressources' stock price today? One share of NEPT stock can currently be purchased for approximately $3.06. How big of a company is Neptune Technologies & Bioressources? Neptune Technologies & Bioressources has a market capitalization of $243.98 million and generates $21.56 million in revenue each year. How can I contact Neptune Technologies & Bioressources? Neptune Technologies & Bioressources' mailing address is 545 PROMENADE DU CENTROPOLIS SUITE 100, LAVAL A8, H7T 0A3. The biotechnology company can be reached via phone at 45-0687-2262 or via email at [email protected] MarketBeat Community Rating for Neptune Technologies & Bioressources (NASDAQ NEPT)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 75 (Vote Outperform)Underperform Votes: 50 (Vote Underperform)Total Votes: 125MarketBeat's community ratings are surveys of what our community members think about Neptune Technologies & Bioressources and other stocks. Vote "Outperform" if you believe NEPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEPT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?